MARKET

APTO

APTO

Aptose Bioscienc
NASDAQ
0.8900
-0.0400
-4.30%
After Hours: 0.9051 +0.0151 +1.70% 17:15 06/14 EDT
OPEN
0.9400
PREV CLOSE
0.9300
HIGH
1.000
LOW
0.8501
VOLUME
133.31K
TURNOVER
0
52 WEEK HIGH
6.31
52 WEEK LOW
0.8501
MARKET CAP
16.12M
P/E (TTM)
-0.1416
1D
5D
1M
3M
1Y
5Y
Aptose Biosciences Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Reiterates Buy on Aptose Biosciences, Maintains $7 Price Target
Benzinga · 2d ago
Tuspetinib: A Promising Candidate for Enhancing r/r AML Treatment Outcomes
TipRanks · 2d ago
Aptose Biosciences Issues Non-Filed Information Disclosure
TipRanks · 2d ago
Aptose Showcases Clinical And Preclinical Results For Tuspetinib (TUS) At The 2024 EHA Hybrid Congress
TUS Monotherapy and TUS+VEN Doublet Therapy show broad clinical activity and strong safety data in relapsed or refractory acute myeloid leukemia. TUS shown to target VEN Resistance Mechanisms and maintain activity on VEN-Resistant AML cells.
Benzinga · 2d ago
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
Aptose Biosciences Inc. Is a clinical-stage precision oncology company developing oral targeted agents to treat hematologic malignancies. Aptose will present at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain.
Barchart · 2d ago
Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 3d ago
Buy Rating on Aptose Biosciences Given Promising Tuspetinib Developments for AML Treatment
TipRanks · 5d ago
More
About APTO
Aptose Biosciences Inc. is a clinical-stage biotechnology company. The Company is engaged in the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase I/II expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase I a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies.

Webull offers Aptose Biosciences Inc stock information, including NASDAQ: APTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APTO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APTO stock methods without spending real money on the virtual paper trading platform.